≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Osteogenesis imperfecta

Endpoint Browser PheWeb

Q17_OSTEOGEN_IMPERFECTA

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — Q78.00
  • Cause of death: ICD-10 — Q78.00

2 out of 7 registries used, show all original rules.

86

4. Check minimum number of events

None

86

5. Include endpoints

None

86

6. Filter based on genotype QC (FinnGen only)

83

Control definitions (FinnGen only)

Control exclude
Q17_CONGEN_MALFO_DEFORMAT_MUSCULOS_SYSTEM

Extra metadata

First used in FinnGen datafreeze
DF12

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded (different definition than used in FinnGen).

-FinnGen-

Key figures

All Female Male
Number of individuals 83 59 24
Unadjusted period prevalence (%) 0.02 0.02 0.01
Median age at first event (years) 33.36 32.19 36.24

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
86
Matched controls
860
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
Q78.00
ICD-10 Finland
Congenital osteogenesis imperfecta
+∞
123.8
86
*
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
42.2
66.5
48
25
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
20.3
42.2
41
37
NA2AA
NOMESCO Finland
Thoracal spine X-ray examination without contrast
124.9
31.3
32
*
Z31.5
ICD-10 Finland
Genetic counselling
14.7
30.0
33
35
X58
ICD-10 Finland
Exposure to other specified factors
8.9
22.4
39
73
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
8.3
21.5
58
171
X59
ICD-10 Finland
Exposure to unspecified factor
8.0
21.5
49
122
NG4AA
NOMESCO Finland
Lower leg X-ray examination
26.6
21.0
29
16
75650
ICD-8 Finland
Other congenital anomalies of musculoskeletal system, Chondrodystrophy
+∞
20.6
19
*
Q78.08
ICD-10 Finland
Osteogenesis imperfecta tarda
+∞
20.6
19
*
Z01.1
ICD-10 Finland
Examination of ears and hearing
7.1
17.5
37
83
7564A
ICD-9 Finland
Other congenital musculoskeletal anomalies, Chondrodystrophy
+∞
17.3
16
*
S72.3
ICD-10 Finland
Fracture of shaft of femur
208.9
17.2
17
*
M05BA04
ATC
alendronic acid; oral
20.4
15.5
23
15
ZX120
NOMESCO Finland
Intravenous
8.4
15.5
24
38
TNX34
NOMESCO Finland
Major custom molded cast, unspecified region
44.8
15.1
18
5
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
5.8
15.1
50
166
NF3AA
NOMESCO Finland
Femur X-ray examination
26.6
14.1
19
9
NFJ60
NOMESCO Finland
Internal fixation of fracture of other parts of femur with intramedullary nail
89.4
14.1
15
*
DFF00
NOMESCO Finland
Pure tone audiometry
7.3
14.0
25
46
W19
ICD-10 Finland
Unspecified fall
7.3
14.0
25
46
5BA08, ,
NOMESCO Finland
+∞
13.9
13
*
S82.2
ICD-10 Finland
Fracture of shaft of tibia
23.9
13.6
19
10
L28
ICPC
Limited function/disability (L)
6.3
13.6
29
64
H90.6
ICD-10 Finland
Mixed conductive and sensorineural hearing loss, bilateral
34.7
13.6
17
6
NG1AA
NOMESCO Finland
Knee X-ray examination without contrast
6.4
13.5
28
60
R4110
NOMESCO Finland
Physiotherapy
5.3
13.5
48
166
TNX33
NOMESCO Finland
Custom moulded cast, unspecified region
13.2
13.0
23
23
H05BA01
ATC
calcitonin (salmon synthetic); nasal, parenteral
151.1
12.8
13
*
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
6.4
12.3
25
52
NH1AA
NOMESCO Finland
Ankle X-ray examination without contrast
6.8
12.3
23
44
TPH04
NOMESCO Finland
Cathetrisation of vein
5.2
12.2
35
100
Z3226
NOMESCO Finland
Physiotherapist
4.9
11.7
39
125
H90.0
ICD-10 Finland
Conductive hearing loss, bilateral
+∞
11.7
11
*
NE1AA
NOMESCO Finland
Pelvis X-ray examination
11.4
11.7
22
25
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
6.1
11.5
24
51
ZXA05
NOMESCO Finland
Left side
5.0
11.1
32
91
NF1AA
NOMESCO Finland
Hip X-ray examination
10.7
10.8
21
25
Z3229
NOMESCO Finland
Other healthcare associate professional
6.6
10.7
20
38
M05BA07
ATC
risedronic acid; oral
124.6
10.7
11
*
H90.3
ICD-10 Finland
Sensorineural hearing loss, bilateral
5.5
10.5
25
60
TNX50
NOMESCO Finland
Removal of cutom molded cast and internal stretch
9.9
10.4
21
27
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
5.4
9.9
24
58
NFU20
NOMESCO Finland
Removal of internal fixation device from femur
62.3
9.9
11
*
ZXD05
NOMESCO Finland
Urgent procedure
4.1
9.7
42
161
9128
FHL
Open reduction and osteosynthesis
111.8
9.6
10
*
WX1PA
NOMESCO Finland
Total body mineral density measurement with Dual energy X-ray absorptiometry (DXA)
111.8
9.6
10
*
W00
ICD-10 Finland
Fall on same level involving ice and snow
5.1
9.2
23
57
E883A
ICD-9 Finland
Fall into hole or other opening in surface
13.7
9.0
15
13
M81.9
ICD-10 Finland
Osteoporosis, unspecified
14.9
8.7
14
11
9165
FHL
Removal of osteosynthesis material
31.1
8.7
11
*
K00.51
ICD-10 Finland
Dentinogenesis imperfecta
+∞
8.5
8
*
5BA03, ,
NOMESCO Finland
+∞
8.5
8
*
N02AX02
ATC
tramadol; systemic, rectal
3.7
8.3
46
204
Z2221
NOMESCO Finland
Medical doctor
3.7
8.1
41
171
S82.3
ICD-10 Finland
Fracture of lower end of tibia
13.7
7.9
13
11
S72.0
ICD-10 Finland
Fracture of neck of femur
20.7
7.8
11
6
NE1AD
NOMESCO Finland
Pelvis and hip bones CT examination
27.9
7.8
10
*
ZXA00
NOMESCO Finland
Right side
3.8
7.7
31
110
Z3231
NOMESCO Finland
Registered nurse
3.6
7.6
40
169
ZXE20
NOMESCO Finland
More than three and less than five hours
4.5
7.6
22
61
R5110, ,
SPAT
7.9
7.6
17
26
NB1AA
NOMESCO Finland
Shoulder X-ray examination without contrast
5.3
7.6
17
38
3870A
ICD-9 Finland
Otosclerosis involving oval window, nonobliterative
+∞
7.4
7
*
RK120, ,
NOMESCO Finland
+∞
7.4
7
*
NCU20
NOMESCO Finland
Removal of internal fixation device from elbow or forearm
22.3
7.3
10
5
A28
ICPC
Limited function/disability NOS
4.6
7.3
20
53
NGJ60
NOMESCO Finland
Internal fixation of fracture of knee or lower leg using intramedullary nail, other or unspecified
33.1
7.3
9
*
ZXE03
NOMESCO Finland
Procedure duration 20 to 29 minutes
7.9
7.2
16
24
ND1AA
NOMESCO Finland
Wrist X-ray examination
5.1
7.1
17
40
EBA15
NOMESCO Finland
Extraction of multiple teeth
15.5
7.1
11
8
S22.4
ICD-10 Finland
Multiple fractures of ribs
43.6
6.9
8
*
NC1AA
NOMESCO Finland
Elbow X-ray examination without contrast
10.0
6.8
13
15
S42.1
ICD-10 Finland
Fracture of scapula
24.8
6.8
9
*
TNG34
NOMESCO Finland
Major custom moulded orthopaedic cast, knee or lower leg
24.8
6.8
9
*
N03AX16
ATC
[U] pregabalin
3.8
6.8
25
83
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
4.6
6.7
18
47
WX212
NOMESCO Finland
Femoral plexus blockade
15.9
6.6
10
7
S70.0
ICD-10 Finland
Contusion of hip
10.5
6.5
12
13
S72.4
ICD-10 Finland
Fracture of lower end of femur
75.2
6.5
7
*
ZXE10
NOMESCO Finland
More than one and less than three hours
3.2
6.5
43
206
Z71.8
ICD-10 Finland
Other specified counselling
3.2
6.4
45
222
NCJ62
NOMESCO Finland
Internal fixation of fracture of forearm using plate
19.8
6.4
9
5
XG466
NOMESCO Finland
Sleep oxymetry
19.8
6.4
9
5
S82.1
ICD-10 Finland
Fracture of upper end of tibia
19.8
6.4
9
5
H80.0
ICD-10 Finland
Otosclerosis involving oval window, nonobliterative
29.0
6.3
8
*
TQW40
NOMESCO Finland
Remowal of suture of skin
7.0
6.3
15
25
38699, ,
ICD-8 Finland
+∞
6.3
6
*
NGJ62
NOMESCO Finland
Internal fixation of fracture of knee or lower leg using plate and screws, other or unspecified
+∞
6.3
6
*
NFK30
NOMESCO Finland
Angulation, rotation or displacement osteotomy of femur
+∞
6.3
6
*
Q78.9
ICD-10 Finland
Osteochondrodysplasia, unspecified
+∞
6.3
6
*
NGK30
NOMESCO Finland
Angulation, rotation or displacement osteotomy of knee or lower leg
+∞
6.3
6
*
ZXD35
NOMESCO Finland
Usual procedure
13.9
6.3
10
8
NK6MA
NOMESCO Finland
Measurement of bone age from hand and elbow using X-ray
8.3
6.2
13
18
R5130
NOMESCO Finland
Repair work or maintenance done on the aid
16.5
6.0
9
6
M01AH02
ATC
rofecoxib; oral
4.6
6.0
16
41
SPAT1229
SPAT
Assessment of need for aid
7.8
6.0
13
19

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
calcium (different salts in combination); oral
A12AA20 [21600872]
1.9e+00
2.3e+00
—
—
2.8e+00
2.8e+00
2.7e+00
cases:18.06%
controls:3.12%
cases:18.92%
controls:2.36%
—
—
—
—
cases:10.81%
controls:0.70%
cases:28.38%
controls:2.37%
cases:40.28%
controls:4.19%
13
22
59
684
14
17
60
702
—
—
8
5
66
714
21
17
53
701
29
29
43
663
Outpatient Visit
OP [9202]
7.0e-01
1.1e+00
1.4e+00
—
1.4e+00
1.7e+00
2.4e+00
cases:66.67%
controls:49.86%
cases:58.11%
controls:31.43%
cases:25.68%
controls:8.21%
—
—
cases:24.32%
controls:7.23%
cases:74.32%
controls:34.54%
cases:95.83%
controls:67.63%
48
352
24
354
43
226
31
493
19
59
55
660
—
18
52
56
667
55
248
19
470
69
468
3
224
Endocrinology
46 [38004485]
1.5e+00
—
—
1.0e+50
—
2.9e+00
2.8e+00
cases:6.94%
controls:1.70%
—
—
—
—
cases:18.92%
controls:0.00%
—
—
cases:22.97%
controls:1.53%
cases:38.89%
controls:3.90%
5
12
67
694
—
—
14
0
60
719
—
17
11
57
707
28
27
44
665
Orthopedic Surgery
20 [38004465]
1.5e+00
1.3e+00
—
1.0e+50
—
2.0e+00
1.6e+00
cases:26.39%
controls:7.08%
cases:9.46%
controls:2.64%
—
—
cases:8.11%
controls:0.00%
—
—
cases:17.57%
controls:2.92%
cases:34.72%
controls:9.39%
19
50
53
656
7
19
67
700
—
6
0
68
719
—
13
21
61
697
25
65
47
627
Emergency Room Visit
ER [9203]
1.1e+00
1.3e+00
—
—
—
1.1e+00
1.0e+00
cases:45.83%
controls:22.66%
cases:28.38%
controls:9.60%
—
—
—
—
—
—
cases:21.62%
controls:8.77%
cases:48.61%
controls:25.87%
33
160
39
546
21
69
53
650
—
—
—
16
63
58
655
35
179
37
513
Fall on same level from slipping, tripping and stumbling
W01 [45756243]
2.3e+00
—
—
—
—
1.9e+00
2.1e+00
cases:13.89%
controls:1.56%
—
—
—
—
—
—
—
—
cases:6.76%
controls:1.11%
cases:12.50%
controls:1.73%
10
11
62
695
—
—
—
—
5
8
69
710
9
12
63
680
Outpatient Hospital
22 [8756]
7.7e-01
1.2e+00
-1.0e+50
1.0e+50
—
1.4e+00
1.3e+00
cases:36.11%
controls:20.82%
cases:17.57%
controls:5.98%
cases:0.00%
controls:1.11%
cases:9.46%
controls:0.00%
—
—
cases:21.62%
controls:6.41%
cases:44.44%
controls:17.20%
26
147
46
559
13
43
61
676
0
8
74
711
7
0
67
719
—
16
46
58
672
32
119
40
573
Physical Medicine And Rehabilitation
25 [38004468]
1.1e+00
—
—
—
—
2.0e+00
1.6e+00
cases:11.11%
controls:3.97%
—
—
—
—
—
—
—
—
cases:13.51%
controls:2.09%
cases:26.39%
controls:6.50%
8
28
64
678
—
—
—
—
10
15
64
703
19
45
53
647
Clinical Cytogenetics and Genomics
OMOP4822000 [32411]
—
—
—
1.0e+50
—
—
2.9e+00
—
—
—
—
—
—
cases:9.46%
controls:0.00%
—
—
—
—
cases:15.28%
controls:1.01%
—
—
—
7
0
67
719
—
—
11
7
61
685
Otolaryngology
4 [38004449]
3.9e-01
1.4e+00
—
1.0e+50
—
1.6e+00
1.1e+00
cases:12.50%
controls:8.78%
cases:12.16%
controls:3.34%
—
—
cases:12.16%
controls:0.00%
—
—
cases:12.16%
controls:2.65%
cases:26.39%
controls:10.69%
9
62
63
644
9
24
65
695
—
9
0
65
719
—
9
19
65
699
19
74
53
618
General Surgery
2 [38004447]
1.2e+00
1.3e+00
—
—
—
1.4e+00
7.2e-01
cases:34.72%
controls:13.74%
cases:14.86%
controls:4.45%
—
—
—
—
—
—
cases:17.57%
controls:5.15%
cases:27.78%
controls:15.75%
25
97
47
609
11
32
63
687
—
—
—
13
37
61
681
20
109
52
583
Foot and toes X-ray examination
NH3AA [2001308267]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.33%
controls:0.72%
—
—
—
—
—
—
6
5
66
687
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
—
1.7e+00
—
—
—
2.4e+00
1.3e+00
—
—
cases:6.76%
controls:1.25%
—
—
—
—
—
—
cases:9.46%
controls:0.97%
cases:13.89%
controls:4.34%
—
5
9
69
710
—
—
—
7
7
67
711
10
30
62
662
Intravenous
ZX120 [2001311495]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.33%
controls:0.87%
—
—
—
—
—
—
6
6
66
686
Exposure to unspecified factor
X59 [45756412]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:13.89%
controls:1.59%
—
—
—
—
—
—
10
11
62
681
Treatment of a patient needing special arrangements
WYA30 [2001310874]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.33%
controls:1.01%
—
—
—
—
—
—
6
7
66
685
Right side
ZXA00 [2001311346]
2.2e+00
—
—
—
—
—
—
cases:11.11%
controls:1.42%
—
—
—
—
—
—
—
—
—
—
—
—
8
10
64
696
—
—
—
—
—
—
Telephone prescription or other care instructions
WZB00 [2001310884]
—
-1.0e+50
—
—
—
—
2.1e+00
—
—
cases:0.00%
controls:1.11%
—
—
—
—
—
—
—
—
cases:13.89%
controls:1.88%
—
0
8
74
711
—
—
—
—
10
13
62
679
One hour or less
ZXE00 [2001311394]
6.8e-01
—
—
—
—
2.1e+00
6.3e-01
cases:8.33%
controls:4.39%
—
—
—
—
—
—
—
—
cases:9.46%
controls:1.25%
cases:8.33%
controls:4.62%
6
31
66
675
—
—
—
—
7
9
67
709
6
32
66
660
Pain in joint
M25.5 [45586941]
2.1e+00
-1.0e+50
—
—
—
—
—
cases:8.33%
controls:1.13%
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
6
8
66
698
0
6
74
713
—
—
—
—
—
pH of Serum or Plasma
2753-2 [3018418]
—
—
—
—
—
2.3e+00
2.1e+00
—
—
—
—
—
—
—
—
—
—
cases:6.76%
controls:0.70%
cases:13.89%
controls:2.02%
—
—
—
—
—
5
5
69
713
10
14
62
678
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
1.4e+00
—
—
—
—
2.0e+00
1.3e+00
cases:12.50%
controls:3.40%
—
—
—
—
—
—
—
—
cases:9.46%
controls:1.39%
cases:13.89%
controls:4.34%
9
24
63
682
—
—
—
—
7
10
67
708
10
30
62
662
Urgent procedure
ZXD05 [2001311386]
9.9e-01
—
—
—
—
—
2.0e+00
cases:6.94%
controls:2.69%
—
—
—
—
—
—
—
—
—
—
cases:9.72%
controls:1.45%
5
19
67
687
—
—
—
—
—
7
10
65
682
Left side
ZXA05 [2001311347]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:13.89%
controls:2.17%
—
—
—
—
—
—
10
15
62
677
Pediatric Surgery
OMOP4822020 [45756819]
1.6e+00
—
—
—
—
—
1.9e+00
cases:6.94%
controls:1.42%
—
—
—
—
—
—
—
—
—
—
cases:12.50%
controls:2.02%
5
10
67
696
—
—
—
—
—
9
14
63
678
Sensorineural hearing loss, bilateral
H90.3 [45576850]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.72%
controls:1.59%
—
—
—
—
—
—
7
11
65
681
Basic examination of mouth
SAA02 [2001310275]
2.4e-01
—
—
—
—
1.9e+00
4.0e-01
cases:9.72%
controls:7.79%
—
—
—
—
—
—
—
—
cases:12.16%
controls:2.09%
cases:16.67%
controls:11.85%
7
55
65
651
—
—
—
—
9
15
65
703
12
82
60
610
Physiotherapy
R4110 [2001310233]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:13.89%
controls:2.46%
—
—
—
—
—
—
10
17
62
675
Infiltration anesthesia
WX110 [2001310767]
1.9e-01
—
—
—
—
1.7e+00
4.2e-01
cases:11.11%
controls:9.35%
—
—
—
—
—
—
—
—
cases:10.81%
controls:2.23%
cases:15.28%
controls:10.55%
8
66
64
640
—
—
—
—
8
16
66
702
11
73
61
619
Audiology
64 [38004489]
2.2e+00
—
—
—
—
—
1.7e+00
cases:6.94%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
cases:11.11%
controls:2.31%
5
6
67
700
—
—
—
—
—
8
16
64
676
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
—
2.0e+00
—
—
—
1.9e+00
1.5e+00
—
—
cases:6.76%
controls:0.97%
—
—
—
—
—
—
cases:8.11%
controls:1.25%
cases:13.89%
controls:3.32%
—
5
7
69
712
—
—
—
6
9
68
709
10
23
62
669
Scheduled procedure
ZXD10 [2001311387]
7.9e-01
—
—
—
—
1.5e+00
1.5e+00
cases:8.33%
controls:3.97%
—
—
—
—
—
—
—
—
cases:6.76%
controls:1.53%
cases:15.28%
controls:3.90%
6
28
66
678
—
—
—
—
5
11
69
707
11
27
61
665
piroxicam; oral, parenteral, rectal
M01AC01 [21603961]
1.3e+00
—
—
—
—
—
9.0e-01
cases:16.67%
controls:4.96%
—
—
—
—
—
—
—
—
—
—
cases:9.72%
controls:4.19%
12
35
60
671
—
—
—
—
—
7
29
65
663
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
—
2.0e+00
—
—
—
1.7e+00
1.3e+00
—
—
cases:6.76%
controls:0.97%
—
—
—
—
—
—
cases:9.46%
controls:1.95%
cases:16.67%
controls:5.20%
—
5
7
69
712
—
—
—
7
14
67
704
12
36
60
656
Inpatient Hospital
21 [8717]
6.0e-01
6.5e-01
—
1.0e+50
1.7e+00
5.4e-01
1.0e+00
cases:45.83%
controls:31.73%
cases:18.92%
controls:10.85%
—
—
cases:14.86%
controls:0.00%
cases:8.11%
controls:1.53%
cases:16.22%
controls:10.17%
cases:50.00%
controls:26.16%
33
224
39
482
14
78
60
641
—
11
0
63
719
6
11
68
708
12
73
62
645
36
181
36
511
pH of Urine
2756-5 [3015736]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.37%
—
—
—
—
—
—
—
0
17
74
701
—
Preparing and fitting the occlusal splint in the mouth
SHB00 [2001310410]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
72
700
—
—
—
—
—
—
amlodipine; oral
C08CA01 [21601747]
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
cases:0.00%
controls:2.83%
—
—
—
—
—
—
cases:0.00%
controls:0.83%
cases:0.00%
controls:2.65%
—
—
0
20
72
686
—
—
—
0
6
74
713
0
19
74
699
—
desogestrel
G03AC09 [21602505]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
0
5
72
701
—
—
—
—
—
0
5
72
687
metoprolol; oral, parenteral
C07AB02 [21601684]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.97%
—
—
—
—
—
—
—
—
0
7
74
712
—
—
More than three and less than five hours
ZXE20 [2001311408]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
72
700
—
—
—
—
—
—
Medication, disinfection of root canals
SGC00 [2001310392]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
72
700
—
—
—
—
—
—
Coronary angiography
AN1 [2000200163]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.42%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
72
696
—
—
—
—
—
—
drospirenone and estetrol
G03AA18 [947983]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
5
72
687
Varicose veins of lower extremities without ulcer or inflammation
I83.9 [45552859]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
72
699
—
—
—
—
—
—
Cholesterol in HDL [Moles/volume] in Serum or Plasma
14646-4 [3023602]
—
1.1e+00
-1.0e+50
—
-1.0e+50
—
-1.7e-01
—
—
cases:10.81%
controls:4.03%
cases:0.00%
controls:0.70%
—
—
cases:0.00%
controls:0.83%
—
—
cases:12.50%
controls:14.45%
—
8
29
66
690
0
5
74
714
—
0
6
74
713
—
9
100
63
592
hydroxyzine; oral, parenteral
N05BB01 [21604590]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
0
6
74
713
—
—
—
—
—
Other angina pectoris stenosed coronary artery
I20.81 [2000502397]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
72
700
—
—
—
—
—
—
Chronic rhinitis
J31.0 [45572165]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
6
72
686
mometasone
D07AC13 [21602132]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.97%
—
—
—
—
—
—
—
—
—
—
—
0
7
74
712
—
—
—
—
—
Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.73%
—
—
—
—
—
—
0
12
72
680
Respiratory and circulatory monitoring
WX700 [2001310817]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
0
5
74
713
—
Derangement of meniscus due to old tear or injury
M23.2 [45591779]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.16%
—
—
—
—
—
—
0
8
72
684
lercanidipine; oral
C08CA13 [21601759]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.13%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
72
698
—
—
—
—
—
—
loperamide oxide; oral
A07DA05 [21600648]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
72
701
—
—
—
—
—
—
Personal history of diseases of the digestive system
Z87.1 [45542474]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
0
5
74
713
—
levocetirizine; oral
R06AE09 [21603498]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
72
700
—
—
—
—
—
—
valproic acid; oral, parenteral, rectal
N03AG01 [21604422]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
cases:0.00%
controls:1.16%
—
—
—
—
—
0
6
74
712
0
8
72
684
Joint ultrasound examination not elsewhere classified
NK4XE [2001308469]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
72
701
—
—
—
—
—
—
fluticasone; nasal
R01AD08 [21605050]
—
—
—
—
—
-1.0e+50
-8.5e-02
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.09%
cases:6.94%
controls:7.51%
—
—
—
—
—
0
15
74
703
5
52
67
640
Case Management Agency
251B00000X [38004193]
7.3e-02
-4.4e-02
—
—
5.0e-01
1.5e-01
2.2e-01
cases:30.56%
controls:29.04%
cases:18.92%
controls:19.61%
—
—
—
—
cases:13.51%
controls:8.62%
cases:27.03%
controls:24.23%
cases:47.22%
controls:41.91%
22
205
50
501
14
141
60
578
—
—
10
62
64
657
20
174
54
544
34
290
38
402
sulfadiazine and trimethoprim
J01EE02 [21602962]
1.7e-01
-1.0e+50
—
—
—
-1.0e+50
—
cases:6.94%
controls:5.95%
cases:0.00%
controls:0.97%
—
—
—
—
—
—
cases:0.00%
controls:1.25%
—
—
5
42
67
664
0
7
74
712
—
—
—
0
9
74
709
—
Carboxyhemoglobin/Hemoglobin.total in Blood
20563-3 [3023081]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
5
72
687
rabeprazole; oral
A02BC04 [21600099]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
0
5
72
701
—
—
—
—
—
0
6
72
686
insulin (human); parenteral
A10AB01 [21600715]
-1.0e+50
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
-1.0e+50
cases:0.00%
controls:9.92%
cases:0.00%
controls:7.51%
cases:0.00%
controls:2.78%
—
—
cases:0.00%
controls:1.67%
cases:0.00%
controls:7.10%
cases:0.00%
controls:7.08%
0
70
72
636
0
54
74
665
0
20
74
699
—
0
12
74
707
0
51
74
667
0
49
72
643
Single live birth
Z37.0 [45571346]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
5
72
687
SMOKING - SMOKE2: no - SMOKE3: never - SMOKE5: never
SMOKING-2-3-5 [2002330114]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:2.78%
—
—
—
—
—
—
—
—
—
—
—
0
20
74
699
—
—
—
—
—
Social worker
Z2446 [2001311559]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
7
72
685
Pain in limb
M79.6 [45587063]
1.5e+00
—
—
—
—
—
1.0e+00
cases:6.94%
controls:1.56%
—
—
—
—
—
—
—
—
—
—
cases:11.11%
controls:4.19%
5
11
67
695
—
—
—
—
—
8
29
64
663
Medical doctor
Z2221 [2001311556]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.72%
controls:2.89%
—
—
—
—
—
—
7
20
65
672
Adenotomy
EMB30 [2001302268]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
72
700
—
—
—
—
—
—
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Blood
47598-8 [3048816]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
5
72
687
oxybutynin; oral, transdermal
G04BD04 [21602637]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
72
700
—
—
—
—
—
—
Sterilization
Z30.2 [45609921]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
0
5
72
701
—
—
—
—
—
0
6
72
686
hydrocortisone buteprate
D07AB11 [21602115]
5.6e-01
—
—
—
—
1.5e+00
7.5e-01
cases:9.72%
controls:5.81%
—
—
—
—
—
—
—
—
cases:8.11%
controls:1.95%
cases:13.89%
controls:7.08%
7
41
65
665
—
—
—
—
6
14
68
704
10
49
62
643
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
0
5
74
714
—
—
—
—
—
Bilirubin.conjugated [Moles/volume] in Serum or Plasma
29760-6 [3005772]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
6
72
686
Medical Oncology
90 [38004507]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.94%
controls:2.02%
—
—
—
—
—
—
5
14
67
678
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.11%
cases:0.00%
controls:2.75%
0
7
72
699
—
—
—
—
0
8
74
710
0
19
72
673
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:3.32%
—
—
—
—
—
—
0
23
72
669
Chronic coronary artery disease and dyslipidaemia associated with chronic coronary artery disease
206 [2001600204]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
5
72
687
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
—
1.2e+00
—
—
—
—
—
—
—
cases:6.76%
controls:2.23%
—
—
—
—
—
—
—
—
—
—
—
5
16
69
703
—
—
—
—
—
trimethoprim; oral, parenteral
J01EA01 [21602931]
7.1e-01
—
—
—
—
-1.0e+50
9.7e-01
cases:6.94%
controls:3.54%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.11%
cases:8.33%
controls:3.32%
5
25
67
681
—
—
—
—
0
8
74
710
6
23
66
669
Other primary gonarthrosis
M17.1 [45596493]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.56%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
72
695
—
—
—
—
—
—
ibuprofen
R02AX02 [1588667]
3.8e-01
3.2e-01
—
—
—
6.0e-01
5.4e-01
cases:31.94%
controls:24.22%
cases:13.51%
controls:10.15%
—
—
—
—
—
—
cases:17.57%
controls:10.45%
cases:41.67%
controls:29.34%
23
171
49
535
10
73
64
646
—
—
—
13
75
61
643
30
203
42
489
pseudoephedrine, combinations; oral
R01BA52 [21603213]
2.4e-01
—
-1.0e+50
—
—
—
-2.5e-02
cases:12.50%
controls:10.06%
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
cases:8.33%
controls:8.53%
9
71
63
635
—
0
5
74
714
—
—
—
6
59
66
633
Other complicated root filling
SGB30 [2001310390]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
72
701
—
—
—
—
—
—
Anxiety disorder, unspecified
F41.9 [45542849]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
72
701
—
—
—
—
—
—
ketoprofen; oral, parenteral, rectal
M01AE03 [21603969]
6.3e-01
—
—
—
—
—
—
cases:11.11%
controls:6.23%
—
—
—
—
—
—
—
—
—
—
—
—
8
44
64
662
—
—
—
—
—
—
Dental calculus supragingival
K03.64 [2000502689]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
0
6
74
713
—
—
—
—
—
celecoxib; oral
M01AH01 [21603992]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.33%
controls:2.17%
—
—
—
—
—
—
6
15
66
677
amitriptyline; oral, parenteral
N06AA09 [21604696]
1.2e+00
—
—
—
—
—
—
cases:9.72%
controls:3.12%
—
—
—
—
—
—
—
—
—
—
—
—
7
22
65
684
—
—
—
—
—
—
General health counselling
SPAT1312 [2001700413]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.11%
—
—
—
—
—
—
—
—
—
—
—
0
8
74
711
—
—
—
—
—
Pure hypercholesterolaemia
E78.0 [45542771]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
6
72
686
Opiates [Presence] in Urine
3879-4 [3027008]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
5
72
687
miconazole
S02AA13 [21605159]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.13%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
72
698
—
—
—
—
—
—
doxycycline; oral, parenteral
J01AA02 [21602800]
1.9e-01
—
—
—
—
—
4.4e-01
cases:19.44%
controls:16.57%
—
—
—
—
—
—
—
—
—
—
cases:18.06%
controls:12.43%
14
117
58
589
—
—
—
—
—
13
86
59
606
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
—
—
—
—
—
-1.0e+50
9.2e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.11%
cases:6.94%
controls:2.89%
—
—
—
—
—
0
8
74
710
5
20
67
672
General anesthesia, balanced
WX408 [2001310808]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.72%
controls:2.02%
—
—
—
—
—
—
7
14
65
678
Protein [Presence] in Urine by Test strip
20454-5 [3014051]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.67%
—
—
—
—
—
—
—
0
12
74
706
—
Tension-type headache
G44.2 [45581495]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
72
700
—
—
—
—
—
—
Neck symptom/complaint
L01 [2002000626]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
72
701
—
—
—
—
—
—
spironolactone; oral
C03DA01 [21601534]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.16%
—
—
—
—
—
—
0
8
72
684
ephedrine; oral
R03CA02 [21603304]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
5
72
687
norethisterone; oral
G03DC02 [21602553]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
0
5
74
714
—
—
—
—
—
Respiratory symptom/complaint other
R29 [2002000898]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
5
72
687
Caries limited to enamel
K02.0 [45576967]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.59%
—
—
—
—
—
—
0
11
72
681
budesonide; inhalant
R03BA02 [21603285]
1.1e+00
—
—
—
—
—
1.4e+00
cases:8.33%
controls:2.83%
—
—
—
—
—
—
—
—
—
—
cases:11.11%
controls:3.03%
6
20
66
686
—
—
—
—
—
8
21
64
671
betamethasone
A07EA04 [21600656]
—
—
—
—
—
—
6.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.94%
controls:3.61%
—
—
—
—
—
—
5
25
67
667
zolpidem; oral
N05CF02 [21604655]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:2.27%
cases:0.00%
controls:0.97%
—
—
—
—
—
—
—
—
—
—
0
16
72
690
0
7
74
712
—
—
—
—
—
12 lead EKG panel
34534-8 [3044889]
5.5e-01
1.4e+00
—
—
—
—
-4.3e-02
cases:6.94%
controls:4.11%
cases:6.76%
controls:1.67%
—
—
—
—
—
—
—
—
cases:8.33%
controls:8.67%
5
29
67
677
5
12
69
707
—
—
—
—
6
60
66
632
Two-surface restoration
SFA20 [2001310359]
—
—
—
—
-1.0e+50
—
-2.5e-02
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
cases:8.33%
controls:8.53%
—
—
—
—
0
5
74
714
—
6
59
66
633
Feeling depressed
P03 [2002000800]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
0
6
72
700
—
—
—
—
—
0
6
72
686
Periodontal treatment, brief
SDA02 [2001310327]
1.2e+00
—
—
—
—
—
8.4e-01
cases:6.94%
controls:2.12%
—
—
—
—
—
—
—
—
—
—
cases:8.33%
controls:3.76%
5
15
67
691
—
—
—
—
—
6
26
66
666
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
5
72
687
Cardiology
6 [38004451]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
0
6
74
713
—
—
—
—
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.97%
—
—
—
—
—
—
—
0
7
74
711
—
Chronic apical periodontitis
K04.5 [45586691]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
72
700
—
—
—
—
—
—
beclometasone; inhalant
R03BA01 [21603284]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.11%
—
—
—
—
—
—
—
0
8
74
710
—
celecoxib
L01XX33 [21603805]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.33%
controls:2.17%
—
—
—
—
—
—
6
15
66
677
Intramuscular and subcutaneous injection
SPAT1256 [2001700357]
—
—
—
—
—
—
4.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.94%
controls:4.62%
—
—
—
—
—
—
5
32
67
660
Obstetrics / Gynecology
16 [38004461]
2.1e-02
1.1e+00
—
—
—
4.2e-01
3.3e-01
cases:15.28%
controls:15.01%
cases:14.86%
controls:5.29%
—
—
—
—
—
—
cases:9.46%
controls:6.41%
cases:19.44%
controls:14.74%
11
106
61
600
11
38
63
681
—
—
—
7
46
67
672
14
102
58
590
Hyperplasia of prostate
N40 [45563015]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
0
5
72
701
—
—
—
—
—
0
6
72
686
Creatine kinase.MB [Mass/volume] in Serum or Plasma
13969-1 [3005785]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
7
72
685
Migraine without aura [common migraine]
G43.0 [45600784]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
72
701
—
—
—
—
—
—
triamcinolone; nasal
R01AD11 [21605052]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.30%
—
—
—
—
—
—
0
9
72
683
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
—
—
—
—
—
—
7.1e-02
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.33%
controls:7.80%
—
—
—
—
—
—
6
54
66
638
Hypertrophy of adenoids
J35.2 [45552887]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
72
701
—
—
—
—
—
—
Caries of dentine
K02.1 [45548134]
—
—
—
—
—
—
8.6e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:15.28%
controls:7.08%
—
—
—
—
—
—
11
49
61
643
Oral and dental health check by dental hygienist or dental assistant
SAB02 [2001310280]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.88%
—
—
—
—
—
—
0
13
72
679
valaciclovir; oral
J05AB11 [21603137]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.85%
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
0
6
72
700
0
5
74
714
—
—
—
—
—
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.13%
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.75%
0
8
72
698
0
5
74
714
—
—
—
—
0
19
72
673
Conductive hearing loss, bilateral
H90.0 [45605765]
—
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.94%
controls:0.00%
—
—
—
—
—
—
5
0
67
692
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
7.7e-02
6.5e-01
—
—
1.2e+00
6.5e-01
4.0e-01
cases:9.72%
controls:9.07%
cases:13.51%
controls:7.51%
—
—
—
—
cases:6.76%
controls:2.09%
cases:14.86%
controls:8.36%
cases:25.00%
controls:18.21%
7
64
65
642
10
54
64
665
—
—
5
15
69
704
11
60
63
658
18
126
54
566
Laceration/cut
S18 [2002000983]
—
—
—
—
—
—
8.2e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.94%
controls:3.18%
—
—
—
—
—
—
5
22
67
670
hydroxychloroquine; oral
P01BA02 [21604889]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.42%
cases:0.00%
controls:1.25%
—
—
—
—
—
—
—
—
—
—
0
10
72
696
0
9
74
710
—
—
—
—
—
pH of Urine by Test strip
5803-2 [3022621]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
6
72
686
Cholesterol [Moles/volume] in Serum or Plasma
14647-2 [3019900]
—
1.1e+00
-1.0e+50
—
-1.0e+50
—
-5.8e-02
—
—
cases:10.81%
controls:4.03%
cases:0.00%
controls:0.70%
—
—
cases:0.00%
controls:0.83%
—
—
cases:13.89%
controls:14.60%
—
8
29
66
690
0
5
74
714
—
0
6
74
713
—
10
101
62
591
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
5.4e-02
8.5e-01
—
—
—
7.5e-01
-2.1e-01
cases:8.33%
controls:7.93%
cases:12.16%
controls:5.56%
—
—
—
—
—
—
cases:12.16%
controls:6.13%
cases:12.50%
controls:15.03%
6
56
66
650
9
40
65
679
—
—
—
9
44
65
674
9
104
63
588
Sampling
SPAT1263 [2001700364]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.11%
—
—
—
—
—
—
—
0
8
74
710
—
General Practice
1 [38004446]
—
1.0e+00
—
—
-1.0e+50
—
9.8e-01
—
—
cases:6.76%
controls:2.50%
—
—
—
—
cases:0.00%
controls:0.70%
—
—
cases:18.06%
controls:7.66%
—
5
18
69
701
—
—
0
5
74
714
—
13
53
59
639
Counselling and guidance related to nutrition and weight management
SPAT1306 [2001700407]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.45%
—
—
—
—
—
—
0
10
72
682
fluvastatin; oral
C10AA04 [21601859]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
0
6
72
700
—
—
—
—
0
5
74
713
—
sildenafil; oral
G04BE03 [21602648]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.30%
—
—
—
—
—
—
0
9
72
683
Student oral health check consistent with decree to assess need for oral health guidance and services
WYA50 [2001310877]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
72
701
—
—
—
—
—
—
Other specified chronic obstructive pulmonary disease
J44.8 [45586673]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
72
701
—
—
—
—
—
—
loratadine; oral
R06AX13 [21603514]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
0
5
74
714
—
—
—
—
Contraception intrauterine
W12 [2002001212]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
6
72
686
medroxyprogesterone and estradiol
G03AA17 [715900]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
cases:0.00%
controls:0.97%
cases:0.00%
controls:1.30%
—
0
6
74
713
—
—
—
0
7
74
711
0
9
72
683
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
2.3e-01
7.2e-01
—
—
—
5.7e-01
2.2e-01
cases:12.50%
controls:10.20%
cases:16.22%
controls:8.62%
—
—
—
—
—
—
cases:16.22%
controls:9.89%
cases:23.61%
controls:19.80%
9
72
63
634
12
62
62
657
—
—
—
12
71
62
647
17
137
55
555
dexamethasone
C05AA09 [21601613]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
72
699
—
—
—
—
—
—
chloramphenicol
D10AF03 [21602307]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
72
699
—
—
—
—
—
—
telmisartan; oral
C09CA07 [21601830]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
cases:0.00%
controls:0.84%
cases:0.00%
controls:0.87%
—
0
6
74
713
—
—
—
0
6
74
712
0
6
72
686
Sicca syndrome [Sjögren]
M35.0 [45562711]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
0
5
74
713
—
Ileoscopy through colon
UJF30 [2001305028]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
5
72
687
cromoglicic acid
S01GX01 [21605085]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.67%
—
—
—
—
—
—
—
0
12
74
706
—
mirtazapine; oral
N06AX11 [21604740]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.97%
—
—
—
—
—
—
—
—
cases:0.00%
controls:4.48%
—
0
7
74
712
—
—
—
—
0
31
72
661
cefuroxime; oral, parenteral
J01DC02 [21602884]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.16%
—
—
—
—
—
—
0
8
72
684
insulin degludec; parenteral
A10AE06 [43534747]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
5
72
687
Vaccination
SPAT1325 [2001700426]
—
—
—
—
—
—
4.6e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.94%
controls:4.48%
—
—
—
—
—
—
5
31
67
661
Carpal tunnel syndrome
G56.0 [45566891]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.73%
—
—
—
—
—
—
0
12
72
680
Uroflowmetry
44856007 [4261340]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
0
6
72
700
—
—
—
—
—
0
5
72
687
Exposure to other specified factors
X58 [45756411]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.33%
controls:1.73%
—
—
—
—
—
—
6
12
66
680
Other seropositive rheumatoid arthritis
M05.8 [45538634]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.99%
cases:0.00%
controls:1.11%
—
—
—
—
—
—
cases:0.00%
controls:0.84%
cases:0.00%
controls:0.72%
0
7
72
699
0
8
74
711
—
—
—
0
6
74
712
0
5
72
687
SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Immunoassay
96119-3 [36032419]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
6
72
686
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.53%
—
—
—
—
—
—
—
0
11
74
707
—
Opening and preparing the root canals, extremely complicated
SGA04 [2001310382]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
72
700
—
—
—
—
—
—
Pulmonary Disease
29 [38004472]
—
—
—
—
—
—
4.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.94%
controls:4.62%
—
—
—
—
—
—
5
32
67
660
Triglyceride [Moles/volume] in Serum or Plasma --fasting
47210-0 [3048773]
—
9.1e-01
-1.0e+50
—
-1.0e+50
—
-4.8e-01
—
—
cases:9.46%
controls:4.03%
cases:0.00%
controls:0.70%
—
—
cases:0.00%
controls:0.83%
—
—
cases:8.33%
controls:12.86%
—
7
29
67
690
0
5
74
714
—
0
6
74
713
—
6
89
66
603
hydrocortisone; local oral
A01AC03 [21600036]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.73%
0
6
72
700
—
—
—
—
—
0
12
72
680
Spontaneous vertex delivery
O80.0 [45577661]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
cases:0.00%
controls:2.02%
—
—
—
—
—
0
6
74
712
0
14
72
678
Otitis media, unspecified
H66.9 [45547965]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
72
701
—
—
—
—
—
—
Gonarthrosis [arthrosis of knee]
M17 [45601350]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
cases:0.00%
controls:0.87%
0
6
72
700
—
—
—
—
0
5
74
713
0
6
72
686
Clarification/discussion RFE/demand
-48 [2002000119]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
72
701
—
—
—
—
—
—
Oxygen [Partial pressure] adjusted to patient's actual temperature in Venous blood
19258-3 [3004529]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
6
72
686
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
cases:6.76%
controls:0.84%
—
—
—
—
—
—
—
5
6
69
712
—
Osteogenesis imperfecta tarda
Q78.08 [2000503492]
—
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.72%
controls:0.00%
—
—
—
—
—
—
7
0
65
692
amoxicillin; oral, parenteral
J01CA04 [21602823]
3.7e-01
3.2e-01
-1.0e+50
—
—
6.5e-01
4.2e-01
cases:30.56%
controls:23.23%
cases:10.81%
controls:8.07%
cases:0.00%
controls:1.11%
—
—
—
—
cases:13.51%
controls:7.52%
cases:30.56%
controls:22.40%
22
164
50
542
8
58
66
661
0
8
74
711
—
—
10
54
64
664
22
155
50
537
Specific gravity of Urine by Refractometry
5810-7 [3019150]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.97%
cases:0.00%
controls:3.47%
—
—
—
—
—
0
7
74
711
0
24
72
668
Laboratory Visit
OMOP4822461 [32036]
1.5e-01
4.0e-01
1.1e+00
—
3.5e-01
4.6e-01
1.4e-01
cases:13.89%
controls:12.18%
cases:17.57%
controls:12.52%
cases:9.46%
controls:3.48%
—
—
cases:6.76%
controls:4.87%
cases:18.92%
controls:12.81%
cases:25.00%
controls:22.54%
10
86
62
620
13
90
61
629
7
25
67
694
—
5
35
69
684
14
92
60
626
18
156
54
536
fusidic acid
S01AA13 [21603564]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
5
72
687
acrivastine; oral
R06AX18 [21603518]
2.2e-01
—
—
—
—
—
4.8e-01
cases:6.94%
controls:5.67%
—
—
—
—
—
—
—
—
—
—
cases:8.33%
controls:5.35%
5
40
67
666
—
—
—
—
—
6
37
66
655
betamethasone
S02BA07 [21605169]
—
—
—
—
—
—
6.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.94%
controls:3.61%
—
—
—
—
—
—
5
25
67
667
prednisolone
S01BA04 [21603621]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
72
700
—
—
—
—
—
—
methylprednisolone aceponate
D07AC14 [21602133]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
72
699
—
—
—
—
—
—
Bloodpressure measurement
XF600 [2001303376]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
7
72
685
Pulpitis
K04.0 [45591570]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
6
72
686
Diverticular disease of large intestine without perforation or abscess
K57.3 [45567316]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
6
72
686
Observation for other suspected diseases and conditions
Z03.89 [2000503757]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.88%
—
—
—
—
—
—
0
13
72
679
Upper gastrointestinal surgery
106 [44777669]
—
—
—
—
—
-1.0e+50
3.7e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.23%
cases:6.94%
controls:4.91%
—
—
—
—
—
0
16
74
702
5
34
67
658
Rheumatoid factor [Units/volume] in Serum or Plasma
11572-5 [3021614]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
72
701
—
—
—
—
—
—
One-surface restoration
SFA10 [2001310358]
5.8e-01
—
—
—
—
—
2.7e-01
cases:9.72%
controls:5.67%
—
—
—
—
—
—
—
—
—
—
cases:8.33%
controls:6.50%
7
40
65
666
—
—
—
—
—
6
45
66
647
Pediatric Medicine
37 [38004477]
6.0e-01
4.9e-01
—
—
—
8.7e-01
6.9e-01
cases:18.06%
controls:10.76%
cases:12.16%
controls:7.79%
—
—
—
—
—
—
cases:16.22%
controls:7.52%
cases:18.06%
controls:9.97%
13
76
59
630
9
56
65
663
—
—
—
12
54
62
664
13
69
59
623
Lipid panel - Serum or Plasma
100898-6 [1761868]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.09%
—
—
—
—
—
—
—
0
15
74
703
—
clidinium and psycholeptics
A03CA02 [21600204]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
72
699
—
—
—
—
—
—
More than one and less than three hours
ZXE10 [2001311401]
1.0e+00
—
—
—
—
-1.0e+50
1.5e+00
cases:9.72%
controls:3.68%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.11%
cases:11.11%
controls:2.60%
7
26
65
680
—
—
—
—
0
8
74
710
8
18
64
674
Pain localized to upper abdomen
R10.1 [45568111]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.30%
0
7
72
699
—
—
—
—
—
0
9
72
683
Child and Adolescent Psychiatry
OMOP4821986 [45756756]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.13%
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
0
8
72
698
0
6
74
713
—
—
—
—
—
pseudoephedrine; oral
R01BA02 [21603210]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.85%
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
0
6
72
700
0
5
74
714
—
—
—
—
—
ketoprofen, combinations
M01AE53 [21603985]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
72
701
—
—
—
—
—
—
mesalazine; oral, rectal
A07EC02 [21600664]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
6
72
686
Preventive immunization/medic
-44 [2002000115]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
72
701
—
—
—
—
—
—
Surveillance of contraceptive drugs
Z30.4 [45547299]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
72
701
—
—
—
—
—
—
Feeling ill
A05 [2002000146]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
5
72
687
Cholesterol in HDL/Cholesterol.total [Molar ratio] in Serum or Plasma
70200-1 [42868674]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
0
6
72
700
—
—
—
—
—
0
6
72
686
ABO and Rh group [Type] in Blood
882-1 [3003694]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.97%
—
—
—
—
—
—
—
0
7
74
711
—
diphenhydramine, combinations
R06AA52 [21603454]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
0
5
74
714
—
—
—
—
—
brompheniramine, combinations
R06AB51 [21603466]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.25%
—
—
—
—
—
—
—
—
—
—
—
0
9
74
710
—
—
—
—
—
Ophthalmology
18 [38004463]
1.6e-02
—
—
—
—
7.7e-01
3.7e-01
cases:8.33%
controls:8.22%
—
—
—
—
—
—
—
—
cases:10.81%
controls:5.29%
cases:20.83%
controls:15.32%
6
58
66
648
—
—
—
—
8
38
66
680
15
106
57
586
Hordeolum
H00.00 [2000502235]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
5
72
687
levofloxacin
S01AE05 [43534860]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
72
701
—
—
—
—
—
—
Nuclear Ab [Titer] in Serum
29953-7 [3037522]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.13%
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
0
8
72
698
0
5
74
714
—
—
—
—
—
Fever, unspecified
R50.9 [45582716]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
0
5
74
714
—
—
—
—
—
insulin (beef); parenteral
A10AD02 [21600730]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
0
5
74
714
—
—
—
—
metronidazole; oral, rectal
P01AB01 [21604857]
1.1e+00
—
—
—
—
-1.0e+50
8.6e-01
cases:12.50%
controls:4.53%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.97%
cases:9.72%
controls:4.34%
9
32
63
674
—
—
—
—
0
7
74
711
7
30
65
662
Trigger finger
M65.3 [45538828]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
5
72
687
Leukocytes [#/volume] in Blood
26464-8 [3010813]
2.1e-01
7.2e-01
—
—
—
5.7e-01
2.2e-01
cases:12.50%
controls:10.34%
cases:16.22%
controls:8.62%
—
—
—
—
—
—
cases:16.22%
controls:9.89%
cases:23.61%
controls:19.80%
9
73
63
633
12
62
62
657
—
—
—
12
71
62
647
17
137
55
555
Excessive ear wax
H81 [2002000536]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
72
701
—
—
—
—
—
—
Hand/finger symptom/complaint
L12 [2002000636]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
0
5
74
713
—
Examination for driving licence
Z02.4 [45552056]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.16%
—
—
—
—
—
—
0
8
72
684
orphenadrine, combinations
M03BC51 [21604113]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.33%
controls:2.60%
—
—
—
—
—
—
6
18
66
674
methotrexate
L01BA01 [21601423]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.42%
cases:0.00%
controls:1.25%
—
—
—
—
—
—
—
—
—
—
0
10
72
696
0
9
74
710
—
—
—
—
—
Severe depressive episode without psychotic symptoms
F32.2 [45557202]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
72
697
—
—
—
—
—
—
flumetasone and antiinfectives
S02CA02 [21605174]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.42%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
72
696
—
—
—
—
—
—
Panorama tomography of teeth and jaws or similar X-ray examination
EB1HA [2001301913]
—
—
—
—
—
—
6.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.33%
controls:4.77%
—
—
—
—
—
—
6
33
66
659
budesonide; nasal
R01AD05 [21605047]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
72
700
—
—
—
—
—
—
Viral intestinal infection, unspecified
A08.4 [45576230]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
0
5
72
701
—
—
—
—
—
0
6
72
686
doxepin; oral, parenteral
N06AA12 [21604699]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
5
72
687
pantoprazole; oral, parenteral
A02BC02 [21600097]
9.6e-01
1.3e+00
—
—
—
1.2e+00
5.7e-01
cases:13.89%
controls:5.81%
cases:9.46%
controls:2.78%
—
—
—
—
—
—
cases:9.46%
controls:3.06%
cases:15.28%
controls:9.25%
10
41
62
665
7
20
67
699
—
—
—
7
22
67
696
11
64
61
628
betamethasone
C05AA05 [21601610]
—
—
—
—
—
—
6.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.94%
controls:3.61%
—
—
—
—
—
—
5
25
67
667
Other specified urinary incontinence
N39.4 [45577525]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
5
72
687
glibenclamide; oral
A10BB01 [21600750]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
72
701
—
—
—
—
—
—
Headache
R51 [45558474]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
7
72
685
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2.4e-01
9.2e-01
—
—
—
8.0e-01
5.9e-01
cases:9.72%
controls:7.79%
cases:13.51%
controls:5.84%
—
—
—
—
—
—
cases:14.86%
controls:7.24%
cases:25.00%
controls:15.61%
7
55
65
651
10
42
64
677
—
—
—
11
52
63
666
18
108
54
584
IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
6
72
686
Therapeutic discussion
SPAT1240 [2001700341]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
72
699
—
—
—
—
—
—
rizatriptan; oral
N02CC04 [21604379]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
72
701
—
—
—
—
—
—
ambroxol; oral
R05CB06 [21603385]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.13%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
72
698
—
—
—
—
—
—
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2.2e-01
9.0e-01
—
—
—
8.0e-01
5.9e-01
cases:9.72%
controls:7.93%
cases:13.51%
controls:5.98%
—
—
—
—
—
—
cases:14.86%
controls:7.24%
cases:25.00%
controls:15.61%
7
56
65
650
10
43
64
676
—
—
—
11
52
63
666
18
108
54
584
Implementation of physical therapy rehabilitation plan
SPAT1223 [2001700324]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.98%
cases:0.00%
controls:1.39%
—
—
—
—
—
—
—
—
—
—
0
14
72
692
0
10
74
709
—
—
—
—
—
Removal of sutures
SPAT1153 [2001700254]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
0
5
74
714
—
—
—
—
—
Abdominal ultrasound examination
JN3AE [2001305555]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
6
72
686
Necrosis of pulp
K04.1 [45572186]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
72
701
—
—
—
—
—
—
rosuvastatin; oral
C10AA07 [21601862]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.95%
—
—
—
—
—
—
—
0
14
74
704
—
Nursing episode
950 [44777714]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
6
72
686
insulin glargine; parenteral
A10AE04 [21600739]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
0
5
74
714
—
—
—
—
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
5.9e-01
—
—
—
—
—
9.2e-02
cases:6.94%
controls:3.97%
—
—
—
—
—
—
—
—
—
—
cases:8.33%
controls:7.66%
5
28
67
678
—
—
—
—
—
6
53
66
639
Other specified special examinations
Z01.8 [45581003]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.94%
controls:1.73%
—
—
—
—
—
—
5
12
67
680
dextromethorphan; oral
R05DA09 [21603404]
5.2e-01
-1.0e+50
—
—
—
—
—
cases:6.94%
controls:4.25%
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
5
30
67
676
0
5
74
714
—
—
—
—
—
hydrocortisone aceponate
D07AC16 [21602135]
5.6e-01
—
—
—
—
1.5e+00
7.5e-01
cases:9.72%
controls:5.81%
—
—
—
—
—
—
—
—
cases:8.11%
controls:1.95%
cases:13.89%
controls:7.08%
7
41
65
665
—
—
—
—
6
14
68
704
10
49
62
643
Observation for suspected mental and behavioural disorders
Z03.2 [45552060]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
5
72
687
Loss of teeth due to accident, extraction or local periodontal disease
K08.1 [45591573]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.85%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
72
700
—
—
—
—
—
—
dexamethasone
D10AA03 [21602286]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
72
699
—
—
—
—
—
—
Creatinine [Moles/volume] in Urine
14683-7 [3009508]
—
—
—
—
—
—
1.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:12.50%
controls:4.91%
—
—
—
—
—
—
9
34
63
658
glucosamine; oral
M01AX05 [21604002]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
0
6
74
713
—
—
—
—
—
covid-19, RNA-based vaccine
J07BN01 [954934]
—
—
—
—
—
—
1.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:11.11%
controls:9.54%
—
—
—
—
—
—
8
66
64
626
hydrocortisone
C05AA01 [21601608]
4.8e-01
—
—
—
—
1.5e+00
7.5e-01
cases:9.72%
controls:6.23%
—
—
—
—
—
—
—
—
cases:8.11%
controls:1.95%
cases:13.89%
controls:7.08%
7
44
65
662
—
—
—
—
6
14
68
704
10
49
62
643
Plain photography of ocular fundus
CK2S4 [2001301455]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
6
72
686
bupropion; oral
N06AX12 [21604741]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.30%
—
—
—
—
—
—
0
9
72
683
Internal Medicine
11 [38004456]
4.9e-01
8.3e-01
-1.0e+50
—
—
9.8e-01
6.0e-01
cases:22.22%
controls:14.87%
cases:12.16%
controls:5.70%
cases:0.00%
controls:1.25%
—
—
—
—
cases:17.57%
controls:7.38%
cases:31.94%
controls:20.52%
16
105
56
601
9
41
65
678
0
9
74
710
—
—
13
53
61
665
23
142
49
550
Blighted ovum and nonhydatidiform mole
O02.0 [45606529]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
6
72
686
dexrabeprazole
A02BC07 [45893509]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
0
5
72
701
—
—
—
—
—
0
6
72
686
General and Unspecified, Result test/procedure
A60 [2002000194]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
5
72
687
atorvastatin; oral
C10AA05 [21601860]
—
—
-1.0e+50
—
—
—
5.6e-01
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
cases:8.33%
controls:4.91%
—
—
0
6
74
713
—
—
—
6
34
66
658
combinations of penicillins
J01CR50 [21602867]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.42%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
72
696
—
—
—
—
—
—
Epstein Barr virus Ab [Presence] in Serum
49178-7 [3048929]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
5
72
687
Physiotherapist
Z3226 [2001311560]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.94%
controls:1.59%
—
—
—
—
—
—
5
11
67
681
Office Visit
OMOP4822458 [581477]
5.5e-01
7.1e-01
—
—
—
—
9.3e-01
cases:13.89%
controls:8.50%
cases:8.11%
controls:4.17%
—
—
—
—
—
—
—
—
cases:23.61%
controls:10.84%
10
60
62
646
6
30
68
689
—
—
—
—
17
75
55
617
Methemoglobin/Hemoglobin.total in Blood
2614-6 [3007930]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
6
72
686
azelaic acid; ointment
D10AX03 [21602314]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
72
701
—
—
—
—
—
—
Consultation of another employee
SPAT1260 [2001700361]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
72
701
—
—
—
—
—
—
Other chest pain
R07.3 [45597166]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
5
72
687
Bacteria identified in Stool by Culture
625-4 [3025941]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
7
72
685
Extraction of tooth
EBA00 [2001301923]
—
-1.0e+50
—
—
—
2.1e+00
1.1e+00
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
cases:6.76%
controls:0.84%
cases:9.72%
controls:3.47%
—
0
5
74
714
—
—
—
5
6
69
712
7
24
65
668
salbutamol; oral, parenteral
R03CC02 [21603312]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.97%
—
—
—
—
—
—
—
—
—
—
—
0
7
74
712
—
—
—
—
—
Urate [Moles/volume] in Serum or Plasma
14933-6 [3026493]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.27%
cases:0.00%
controls:0.97%
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
0
9
72
697
0
7
74
712
—
—
—
0
6
74
712
—
Folate [Moles/volume] in Serum or Plasma
14732-2 [3021960]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.02%
—
—
—
—
—
—
0
14
72
678
Neuropsychological investigation
XA800 [2001300412]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
5
72
687
hydrocortisone
S02BA01 [21605166]
5.0e-01
—
—
—
—
1.6e+00
6.5e-01
cases:8.33%
controls:5.24%
—
—
—
—
—
—
—
—
cases:8.11%
controls:1.67%
cases:12.50%
controls:6.94%
6
37
66
669
—
—
—
—
6
12
68
706
9
48
63
644
phenylephrine, combinations
R01BA53 [21603214]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.25%
—
—
—
—
—
—
—
—
—
—
—
0
9
74
710
—
—
—
—
—
Supervision of other normal pregnancy
Z34.8 [45537628]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
7
72
685
phenylpropanolamine, combinations; oral
R01BA51 [21603212]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
0
5
74
714
—
—
—
—
—
combinations of corticosteroids
D07XB30 [21602188]
1.8e-01
—
—
—
—
8.8e-01
6.6e-01
cases:11.11%
controls:9.49%
—
—
—
—
—
—
—
—
cases:6.76%
controls:2.92%
cases:16.67%
controls:9.39%
8
67
64
639
—
—
—
—
5
21
69
697
12
65
60
627
Tooth X-ray additional picture
EB1CA [2001301909]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
6
72
686
Maternal care due to uterine scar from previous surgery
O34.2 [45572805]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
0
5
72
687
Insulin-dependent diabetes diabetic hypoglycemic coma
E10.00 [2000501424]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
0
5
72
701
—
—
—
—
—
0
6
72
686
Benign paroxysmal vertigo
H81.1 [45572061]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
72
701
—
—
—
—
—
—
Dizziness and giddiness
R42 [45568132]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.33%
controls:1.59%
—
—
—
—
—
—
6
11
66
681
fluconazole; oral, parenteral
J02AC01 [21603080]
1.1e+00
—
—
—
—
—
3.1e-01
cases:19.44%
controls:7.51%
—
—
—
—
—
—
—
—
—
—
cases:11.11%
controls:8.38%
14
53
58
653
—
—
—
—
—
8
58
64
634
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.13%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
0
8
72
698
—
—
—
—
0
6
74
712
—
diclofenac
D11AX18 [21602355]
1.6e+00
—
—
—
—
-1.0e+50
—
cases:6.94%
controls:1.42%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.97%
—
—
5
10
67
696
—
—
—
—
0
7
74
711
—
moxonidine; oral
C02AC05 [21600401]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
6
72
686
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.97%
—
—
—
—
—
—
cases:0.00%
controls:0.97%
cases:0.00%
controls:3.47%
—
0
7
74
712
—
—
—
0
7
74
711
0
24
72
668
ispaghula (psylla seeds); oral
A06AC01 [21600555]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.27%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.97%
—
—
0
9
72
697
—
—
—
—
0
7
74
711
—
Delivery in a completely normal case[PARTUS SINE COMPLICATIONE]
6500B [2000405100]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
72
699
—
—
—
—
—
—
Contact with and exposure to other communicable diseases
Z20.8 [45542410]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.01%
—
—
—
—
—
—
0
7
72
685
Acute bronchitis, unspecified
J20.9 [45562445]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.97%
—
—
—
—
—
—
—
0
7
74
711
—
temazepam; oral
N05CD07 [21604642]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.97%
—
—
—
—
—
—
—
—
—
—
—
0
7
74
712
—
—
—
—
—
methylprednisolone
D07AA01 [21602101]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
72
699
—
—
—
—
—
—
Type 1 diabetes mellitus
E10 [45576436]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
—
—
—
—
—
—
—
0
6
74
713
—
—
—
—
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
48
98
9.82
26.06
9.2
10.3
1.08
1.22
mmol/l
2.44
48
89
61
206
7.75
19.06
8.4
3.5
7.39
7.39
ph
0.19
53
143
76
356
10.76
15.71
14.5
9.6
1.22
1.21
mmol/l
1.04
70
317
17
6
34.71
13.56
10.0
3.5
2.10
2.68
mmol/l
—
17
6
15
5
35.76
12.11
11.1
1.6
12.42
18.48
mmol/l
—
15
5
17
20
10.29
8.81
1.9
2.8
10.50
1.17
index
—
10
12
26
96
3.45
5.94
7.3
11.1
—
—
—
0
0
38
190
2.79
5.04
4.5
5.9
87.74
93.09
%
0.70
38
190
7
5
15.05
4.66
2.4
2.6
1.00
0.60
index
—
7
5
21
80
3.15
4.47
8.6
12.2
104.62
104.84
mmol/l
0.07
21
80
24
100
2.94
4.38
7.8
9.0
7.36
7.38
ph
1.20
16
62
45
259
2.55
4.35
2.8
2.6
—
—
—
0
0
21
83
3.02
4.19
8.3
9.0
23.27
23.93
mmol/l
0.58
21
83
8
11
7.88
3.95
8.6
17.2
12.55
10.51
%
—
8
11
9
16
6.14
3.77
8.1
12.7
70.63
60.79
%
—
9
16
65
463
2.65
3.77
9.1
12.4
3.89
3.83
e9/l
0.09
49
400
21
93
2.66
3.37
13.0
12.4
25.52
25.08
mmol/l
0.28
21
93
86
779
+∞
3.35
14.3
11.6
—
—
—
0
0
12
36
3.70
3.17
6.7
9.7
1.28
1.38
%
0.10
12
36
12
36
3.70
3.17
6.7
9.6
0.27
0.68
%
5.61
12
36
8
17
5.07
3.00
9.0
12.0
70.25
61.43
%
—
8
17
45
296
2.09
2.83
5.8
8.3
—
—
—
0
0
51
353
2.09
2.79
3.2
3.0
—
—
estimate
—
0
0
16
68
2.66
2.75
7.5
7.5
—
—
—
0
0
11
39
3.08
2.45
7.3
11.7
24.45
25.14
mmol/l
0.29
11
39
58
433
2.04
2.44
6.4
8.2
1.84
2.05
e9/l
1.24
43
386
25
141
2.09
2.29
2.8
2.9
514.95
570.34
mosm/kgh2o
0.46
19
125
7
20
3.71
2.10
1.4
1.2
—
—
—
0
0
57
440
1.88
1.98
6.8
8.6
0.18
0.20
e9/l
0.40
41
385
55
424
1.82
1.88
6.6
8.3
0.53
0.55
e9/l
0.21
39
365
6
17
3.71
1.87
1.8
1.2
0.31
0.66
nmol/l
—
6
11
55
425
1.82
1.85
6.7
8.3
0.04
0.04
e9/l
0.26
39
365
15
75
2.21
1.83
1.5
1.5
—
—
—
0
0
30
196
1.81
1.76
3.0
3.2
2.48
2.73
mg/l
0.30
25
174
10
40
2.69
1.73
7.8
11.8
95.67
93.72
%
—
10
40
39
285
1.67
1.51
5.4
4.5
37.80
73.26
e6/l
0.54
21
188
5
16
3.25
1.46
3.2
5.6
5.42
6.04
pmol/l
—
5
16
25
164
1.74
1.42
6.2
4.8
—
—
—
0
0
0
37
0.00
1.38
0.0
7.2
—
296.52
—
0
23
48
379
1.60
1.31
11.7
12.5
0.00
0.00
e9/l
0.50
32
302
8
35
2.41
1.31
1.1
1.1
—
—
—
0
0
17
102
1.83
1.28
2.5
1.7
—
—
—
0
0
29
207
1.60
1.18
4.6
2.5
—
—
—
0
0
62
696
0.61
1.16
5.6
5.2
2.93
2.74
mmol/l
0.80
55
649
61
686
0.62
1.12
4.8
4.6
1.46
1.48
mmol/l
0.13
55
633
48
391
1.52
1.07
3.1
3.6
91.98
87.36
ug/l
0.06
43
374
11
61
1.92
1.04
2.7
5.9
0.24
0.22
g/l
0.32
11
61
25
180
1.55
0.97
2.0
2.4
205.88
170.86
u/l
0.26
25
173
68
604
1.60
0.96
5.4
4.5
14.62
14.47
pmol/l
0.21
61
561
41
331
1.46
0.91
3.7
3.4
6.38
6.32
ph
0.10
13
179
28
211
1.48
0.88
4.4
3.6
—
—
estimate
—
0
0
36
288
1.43
0.82
2.0
1.8
—
—
—
0
0
31
242
1.44
0.81
4.4
3.7
62.69
39.98
e6/l
0.21
20
179
86
836
+∞
0.80
29.9
21.3
131.56
134.42
g/l
1.02
86
829
86
836
+∞
0.80
29.8
21.2
277.69
261.23
e9/l
1.30
86
822
86
836
+∞
0.80
31.2
21.8
39.63
40.11
%
0.51
86
829
86
836
+∞
0.80
29.8
21.1
88.89
89.37
fl
0.39
86
829
86
836
+∞
0.80
29.7
21.1
29.52
29.85
pg
0.88
86
829
0
24
0.00
0.80
0.0
1.1
—
—
—
0
0
0
26
0.00
0.80
0.0
1.4
—
—
—
0
0
28
215
1.45
0.79
4.5
3.7
0.27
0.13
e6/l
0.73
17
151
6
34
1.82
0.78
1.5
1.6
—
—
—
0
0
47
398
1.40
0.77
4.2
3.8
0.00
0.00
estimate
—
7
70
22
164
1.46
0.72
2.9
2.9
9.22
5.51
e6/l
0.49
16
146
47
402
1.37
0.70
4.3
3.8
0.00
0.00
estimate
—
6
68
32
259
1.38
0.66
8.3
7.5
—
—
—
0
0
59
647
0.72
0.65
3.7
3.9
1.42
1.23
mmol/l
0.40
53
593
22
280
0.71
0.64
2.6
2.9
—
—
—
0
0
8
51
1.63
0.62
5.3
7.2
7.36
7.38
ph
—
8
41
0
21
0.00
0.61
0.0
3.7
—
57.99
—
0
21
0
21
0.00
0.61
0.0
4.1
—
7.41
—
0
21
0
22
0.00
0.60
0.0
1.4
—
—
—
0
0
47
409
1.33
0.60
4.3
3.8
0.00
0.00
estimate
—
7
63
8
54
1.53
0.59
1.0
1.2
—
—
—
0
0
8
54
1.53
0.59
1.0
1.2
—
—
—
0
0
6
36
1.72
0.58
1.5
1.7
—
—
—
0
0
32
268
1.31
0.52
19.7
10.2
1.22
1.13
inr
0.44
26
215
32
271
1.29
0.47
2.2
1.9
110.03
103.65
pmol/l
0.25
14
142
75
711
1.43
0.45
6.1
5.3
1.83
1.87
mu/l
0.06
68
663
14
105
1.40
0.44
1.6
1.9
—
—
—
0
0
8
56
1.47
0.44
1.0
1.2
—
—
—
0
0
56
512
1.27
0.43
5.8
4.5
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
15
0.00
0.41
0.0
1.0
—
—
—
0
0
0
15
0.00
0.41
0.0
5.9
—
—
—
0
0
0
16
0.00
0.41
0.0
1.3
—
—
—
0
0
0
17
0.00
0.41
0.0
1.9
—
—
—
0
0
0
18
0.00
0.40
0.0
3.8
—
8.99
—
0
18
0
18
0.00
0.40
0.0
3.8
—
2.36
—
0
13
0
18
0.00
0.40
0.0
1.9
—
—
—
0
0
0
18
0.00
0.40
0.0
3.8
—
4.99
—
0
18
11
81
1.41
0.38
1.1
1.6
1177.50
1139.97
nmol/l
—
6
67
6
41
1.50
0.37
1.5
1.8
—
—
—
0
0
12
92
1.35
0.34
1.2
1.2
—
—
—
0
0
7
51
1.40
0.32
1.0
1.2
—
—
—
0
0
7
53
1.35
0.32
1.0
1.2
—
—
—
0
0
23
196
1.24
0.31
3.0
3.2
8.47
69.63
mg/l
2.20
14
124
15
182
0.79
0.30
2.2
1.9
—
—
—
0
0
64
671
0.82
0.28
5.0
4.3
5.66
5.72
mmol/l
0.21
57
614
24
271
0.84
0.24
1.3
1.5
0.60
0.87
u/ml
—
5
56
12
146
0.79
0.24
1.7
2.0
—
—
—
0
0
0
11
0.00
0.21
0.0
2.3
—
—
—
0
0
0
11
0.00
0.21
0.0
2.3
—
—
—
0
0
0
11
0.00
0.21
0.0
6.0
—
5.08
—
0
11
0
11
0.00
0.21
0.0
2.3
—
—
—
0
0
0
11
0.00
0.21
0.0
2.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
2.36
—
0
10
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.7
—
91.64
—
0
10
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
77
747
1.29
0.21
18.5
14.1
25.94
22.21
mg/l
0.48
67
590
0
13
0.00
0.21
0.0
1.3
—
—
—
0
0
22
195
1.17
0.20
3.0
4.0
2.02
9.11
mg/mmol
1.67
12
119
18
205
0.85
0.20
5.3
3.7
0.00
0.00
estimate
—
7
67
7
61
1.16
0.18
1.1
1.7
—
—
—
0
0
8
70
1.16
0.17
1.8
1.8
1.27
1.15
g/l
—
8
65
71
690
1.17
0.15
26.8
17.4
331.72
332.97
g/l
0.49
71
690
14
122
1.18
0.15
1.6
1.6
—
—
—
0
0
16
179
0.87
0.14
4.4
5.9
—
—
—
0
0
28
260
1.11
0.13
1.8
1.6
—
—
—
0
0
14
157
0.87
0.12
2.1
3.9
278.36
325.09
umol/l
1.20
14
145
6
57
1.06
0.09
1.0
1.9
—
—
—
0
0
24
225
1.09
0.08
2.2
3.2
104.02
20.49
ng/l
0.43
17
138
8
75
1.07
0.07
1.9
1.7
—
—
—
0
0
7
82
0.84
0.07
1.4
1.5
—
—
—
0
0
7
83
0.83
0.07
1.4
1.4
—
—
—
0
0
9
85
1.07
0.07
1.1
1.3
—
—
—
0
0
8
92
0.86
0.07
2.6
2.9
4.05
4.51
e9/l
—
8
80
20
188
1.08
0.06
2.6
3.4
1.01
1.02
kg/l
0.30
12
124
10
109
0.91
0.04
1.1
1.2
—
—
—
0
0
13
138
0.93
0.03
1.5
1.3
1.08
7.37
u/ml
—
5
56
22
228
0.95
0.02
2.1
2.3
—
—
—
0
0
26
253
1.04
0.01
1.5
1.6
1.99
2.02
g/l
0.04
14
146
15
155
0.96
0.00
1.5
1.8
—
—
—
0
0
20
199
1.01
0.00
2.9
3.3
—
—
—
0
0
0
8
0.00
0.00
0.0
40.1
—
132.13
—
0
8
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
2.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
282.83
—
0
6
0
6
0.00
0.00
0.0
7.0
—
1.65
—
0
6
0
8
0.00
0.00
0.0
6.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
97.17
—
0
6
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
8
0.00
0.00
0.0
5.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
134.70
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
29.14
—
0
7
0
5
0.00
-0.00
0.0
9.6
—
0.66
—
0
5
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
28.40
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
267.80
—
0
5
0
7
0.00
-0.00
0.0
2.0
—
30.29
—
0
7
0
7
0.00
-0.00
0.0
12.1
—
1043.43
—
0
7
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0

Mortality – FinRegistry

↥

This endpoint is excluded (different definition than used in FinnGen).

Relationships between endpoints

↥

Index endpoint: Q17_OSTEOGEN_IMPERFECTA – Osteogenesis imperfecta

GWS hits: -

This endpoint is excluded (different definition than used in FinnGen).